샘플 요청 목록

 카트 문의
시장보고서
상품코드
1526091

세계의 POC 분자진단 시장

Point of Care (POC) Molecular Diagnostics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 597 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

POC 분자진단 세계 시장은 2030년까지 88억 달러에 도달

2023년에 37억 달러로 추정되는 POC 분자진단 세계 시장은 2023-2030년간 CAGR 13.1%로 성장하여 2030년에는 88억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 PCR 기반 POC 분자진단은 CAGR 14.0%를 나타내고, 분석 기간 종료까지 57억 달러에 이를 것으로 예측됩니다. 유전자 시퀀싱 기반 POC 분자진단 부문의 성장률은 분석 기간중 CAGR 10.5%로 추정됩니다.

미국 시장은 15억 달러로 추정, 중국은 CAGR 15.9%로 성장 예측

미국의 POC 분자진단 시장은 2023년에 15억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 10억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2023-2030년간 CAGR은 15.9%를 나타낼 전망입니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 10.7%와 12.2%를 나타낼 것으로 예측됩니다. 유럽에서는 독일이 CAGR 약 12.3%를 나타낼 전망입니다.

세계 POC 분자진단 시장 - 주요 동향 및 촉진요인 요약

POC(Point-of-Care) 분자진단은 중앙 검사실이 아닌 환자 진료 현장 근처에서 분자진단 검사를 시행합니다. 이 기술은 핵산 분석을 통해 질병을 신속하게 검출할 수 있으며, 며칠이 아닌 몇 분에서 몇 시간 내에 결과를 얻을 수 있습니다. POC 분자진단 장비는 일반적으로 휴대용 또는 핸드헬드 형태로 최소한의 교육만으로 쉽게 사용할 수 있도록 설계되었으며, 기존 실험실 기반 검사에 비해 조작 절차가 적고, 최소한의 교육으로 쉽게 사용할 수 있도록 설계되었습니다. 조작 절차가 적습니다. 이 신속하고 편리한 검사 형태는 다른 의료 응용 분야 중에서도 감염, 유전 질환 및 암 관리에 특히 유용합니다.

POC 분자진단의 유용성은 전 세계 의료 환경, 특히 응급실, 중환자실, 기존 검사 시설에 대한 접근이 제한된 원격지 등에서 점점 더 분명하게 드러나고 있습니다. 독감, 코로나19 및 기타 바이러스 감염증의 적시 진단과 같은 감염병 관리에서 POC 테스트는 신속한 격리 결정을 가능하게 함으로써 감염의 확산을 극적으로 억제할 수 있습니다. 또한, 종양학 같은 분야에서는 POC 분자진단을 통해 종양 마커와 돌연변이를 실시간으로 평가하여 치료 시점에 직접 맞춤형 치료 전략을 수립할 수 있습니다. 약국이나 지역 클리닉과 같은 병원 이외의 환경에도 적용 가능한 이 기술은 그 범위와 영향력을 더욱 확대하여 더 많은 사람들이 진단 서비스를 이용할 수 있도록 돕고 있습니다.

POC 분자진단 시장의 성장은 여러 가지 요인에 의해 이루어지고 있으며, POC 장비의 정확성, 속도 및 사용 편의성을 향상시키는 기술 발전은 시장 확대에 크게 기여하고 있습니다. 또한, 동일한 기기에서 여러 검사를 동시에 수행할 수 있는 멀티플렉싱 기능의 발전은 POC 진단의 유용성과 매력을 크게 향상시키고 있습니다. 또한, 전 세계 감염병 부담 증가와 팬데믹 관리에서 신속 진단에 대한 수요 증가는 POC 검사의 중요한 역할을 강조하고 있습니다. 입원일수 단축, 집중 검사 시설에 대한 의존도 감소에 따른 비용 절감 등 경제적 요인도 다양한 의료 현장에서 POC 진단의 채택을 촉진하고 있습니다. 소비자 행동, 특히 즉각적인 의료 서비스 제공에 대한 기대가 높아지고 개인 맞춤형 의료에 대한 인식이 높아지면서 이러한 혁신적인 진단 솔루션에 대한 수요가 더욱 증가하고 있습니다.

조사 대상 기업 예(총 64건)

  • Bayer AG
  • Danaher Corporation
  • DiaSorin SpA
  • Biocartis NV
  • Maxim Biomedical, Inc.
  • AccuBioTech Co., Ltd.
  • Abacus Diagnostica Oy
  • genedrive plc
  • Molbio Diagnostics Pvt. Ltd.
  • Mesa Biotech, Inc.
  • Binx Health
  • Credo Diagnostics Biomedical Pte. Ltd
  • Genestat Molecular Diagnostics, LLC
  • Alveo Technologies
  • ADOR Diagnostics

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 24.08.09

Global Point of Care (POC) Molecular Diagnostics Market to Reach US$8.8 Billion by 2030

The global market for Point of Care (POC) Molecular Diagnostics estimated at US$3.7 Billion in the year 2023, is expected to reach US$8.8 Billion by 2030, growing at a CAGR of 13.1% over the analysis period 2023-2030. PCR-based POC Molecular Diagnostics, one of the segments analyzed in the report, is expected to record a 14.0% CAGR and reach US$5.7 Billion by the end of the analysis period. Growth in the Genetic Sequencing-based POC Molecular Diagnostics segment is estimated at 10.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 15.9% CAGR

The Point of Care (POC) Molecular Diagnostics market in the U.S. is estimated at US$1.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 15.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.7% and 12.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.3% CAGR.

Global Point of Care (POC) Molecular Diagnostics Market - Key Trends and Drivers Summarized

Point of Care (POC) molecular diagnostics involves the performance of molecular diagnostic tests near the site of patient care rather than in a central laboratory. This technology enables the rapid detection of diseases through nucleic acid analysis, providing results within minutes or hours rather than days. The aim is to deliver timely information to healthcare providers, enabling immediate clinical decision-making and treatment initiation. POC molecular diagnostic devices are typically portable or handheld, designed to be easy to use with minimal training, and require fewer operational steps compared to traditional lab-based tests. This rapid and convenient form of testing is particularly valuable for managing infectious diseases, genetic conditions, and cancer, among other medical applications.

The utility of POC molecular diagnostics has become increasingly evident in healthcare settings around the world, particularly in emergency rooms, intensive care units, and remote areas where access to conventional lab facilities may be limited. In infectious disease management, such as the timely diagnosis of influenza, COVID-19, and other viral infections, POC testing can drastically reduce the spread of infections by enabling quick isolation decisions. Additionally, in settings like oncology, POC molecular diagnostics facilitate the real-time assessment of tumor markers and mutations, which can guide personalized treatment strategies directly at the point of care. The technology's adaptability to non-hospital environments, such as pharmacies and community clinics, further extends its reach and impact, making diagnostic services accessible to a broader population.

The growth in the POC molecular diagnostics market is driven by several factors. Technological advancements that enhance the accuracy, speed, and user-friendliness of POC devices are major contributors to market expansion. The ongoing development of multiplexing capabilities, where multiple tests are conducted at the same time on the same device, also significantly boosts the utility and attractiveness of POC diagnostics. Furthermore, the increasing global burden of infectious diseases and the rising demand for rapid diagnostic methods in pandemic management highlight the critical role of POC testing. Economic factors, including cost savings associated with reduced hospital stays and less reliance on centralized laboratory facilities, encourage the adoption of POC diagnostics across various healthcare settings. Consumer behavior, particularly the growing expectation for immediate healthcare delivery and the rising awareness of personalized medicine, further propels the demand for these innovative diagnostic solutions.

Select Competitors (Total 64 Featured) -

  • Bayer AG
  • Danaher Corporation
  • DiaSorin SpA
  • Biocartis NV
  • Maxim Biomedical, Inc.
  • AccuBioTech Co., Ltd.
  • Abacus Diagnostica Oy
  • genedrive plc
  • Molbio Diagnostics Pvt. Ltd.
  • Mesa Biotech, Inc.
  • Binx Health
  • Credo Diagnostics Biomedical Pte. Ltd
  • Genestat Molecular Diagnostics, LLC
  • Alveo Technologies
  • ADOR Diagnostics

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Point of Care (POC) Molecular Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Molecular Diagnostics: Leveraging Molecular Technologies to Monitor Human Diseases
    • Types of Molecular Diagnostics Tests
    • An Introduction to Point of Care (POC) Molecular Diagnostics
    • Molecular Testing Mechanisms
    • Molecular Vs Non-Molecular POCT
    • Global Market Prospects & Outlook
    • PCR Technology Leads the MDx Market
    • Infectious Diseases: The Largest Application Market
    • Reagents and Kits Dominate the Molecular Diagnostics Market
    • Developing Countries Present Strong Growth Prospects
    • Competition
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Point of Care Diagnostics Augurs Well for Molecular POC Diagnostics Market
    • Emphasis on Decentralized Diagnostics Presents Opportunity for POC Testing
    • Growing Prevalence of Infectious Diseases Spurs Need for POC Molecular Diagnostics
    • Infectious Diseases Remain Major Cause of Death in Under Developed Regions: Breakdown of Leading Causes of Death in Sub-Saharan Africa (in %)
    • Infectious Diseases Related Mortality High Among Children Below 5 Years: Breakdown of Leading Causes of Death in Children Below 5 Years (in %)
    • PCR Plays a Vital Role in the Diagnosis of Infectious Diseases
    • Rising Prevalence of Respiratory Infections to Drive Need for POC Molecular Diagnostics
    • Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
    • Rise in Pollution Levels Trigger Increase in Respiratory Diseases, Driving Market Opportunities
    • Percentage Share Breakdown of Global Deaths Linked to Air Pollution
    • Air Pollution Levels (PM2.5 Concentration (μg/m3) for Major Countries Worldwide for 2023
    • Rising Cancer Incidence Drives Focus onto POC Molecular Diagnostics
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2022
    • Number of New Cancer Cases and Deaths (in Million) by Region for 2023
    • Rising Incidence of Hospital Acquired Infections (HAIs) Propels Demand for POC Molecular Diagnostics
    • Sustained Threat of HIV and Sexually Transmitted Diseases Amplify Need for POC Molecular Diagnostics
    • Global HIV Prevalence: Number of People Living with AIDs (in Thousands) by Region for 2022
    • Number of AIDS-Related Deaths (in Thousands) by Region for 2022
    • Rapid HIV Tests: A New Age Diagnostic Weapon against the Killer Disease
    • Home HIV Testing Emerges as a Lucrative Option
    • Molecular Tests Gaining Prominence in GC/Chlamydia Testing Market
    • Molecular Diagnostics Opens New Avenues in Viral Hepatitis Testing
    • Hepatitis B Prevalence Worldwide by Region
    • Demand Continues to Surge for CLIA-Waived Molecular POC Tests
    • Advancements in POC for Molecular Diagnostics to Drive Market Growth
    • Nanotechnology Facilitates Development of for POC Molecular Diagnostics
    • Healthcare Needs of the World's Aging Population: Potential Opportunity in Store
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Increase in Healthcare Spending in Emerging Markets to Propel Demand for POC Molecular Diagnostics
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Elderly Healthcare Expenditure as a % of GDP for 1970, 2010 and 2050
    • Challenges Facing POC Molecular Diagnostics Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for PCR-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for PCR-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for PCR-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Genetic Sequencing-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Genetic Sequencing-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Genetic Sequencing-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Hybridization-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Hybridization-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Hybridization-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Microarray-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Microarray-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Microarray-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Home Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Home Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Home Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Assisted Living Healthcare Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Assisted Living Healthcare Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Assisted Living Healthcare Facilities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Decentralized Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Decentralized Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Decentralized Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 33: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 36: World 16-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 39: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 40: World Point of Care (POC) Molecular Diagnostics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: World 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: China 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: China 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: France 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: France 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Germany 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Italy 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: UK 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Spain 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Russia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Rest of Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Australia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • INDIA
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 176: India Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: India 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: India 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: South Korea 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 223: Argentina 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 232: Brazil 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 241: Mexico 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 250: Rest of Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 262: Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 271: Iran 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 280: Israel 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 289: Saudi Arabia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 298: UAE 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 307: Rest of Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
  • AFRICA
    • Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 316: Africa 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제